NASDAQ: DNLI | Healthcare / Biotechnology / USA |
20.75 | +0.9600 | +4.85% | Vol 1.03M | 1Y Perf -36.24% |
Oct 3rd, 2023 16:00 DELAYED |
BID | 20.17 | ASK | 21.28 | ||
Open | 19.62 | Previous Close | 19.79 | ||
Pre-Market | - | After-Market | 21.48 | ||
- - | 0.73 3.52% |
Target Price | 60.92 | Analyst Rating | Strong Buy 1.29 | |
Potential % | 193.59 | Finscreener Ranking | ★★★★ 54.39 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★ 51.84 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★ 51.72 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 7.15 | Earnings Rating | Strong Buy | |
Market Cap | 2.85B | Earnings Date | 2nd Nov 2023 | |
Alpha | 0.01 | Standard Deviation | 0.18 | |
Beta | 1.26 |
Today's Price Range 19.5720.76 | 52W Range 19.6734.78 | 5 Year PE Ratio Range -37.50136.60 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -7.48% | ||
1 Month | -15.10% | ||
3 Months | -33.32% | ||
6 Months | -15.32% | ||
1 Year | -36.24% | ||
3 Years | -48.54% | ||
5 Years | -6.65% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -13.94 | |||
ROE last 12 Months | -36.26 | |||
ROA (5Y Avg) | -5.82 | |||
ROA last 12 Months | -24.64 | |||
ROC (5Y Avg) | -13.86 | |||
ROC last 12 Months | -31.02 | |||
Return on invested Capital Q | -11.36 | |||
Return on invested Capital Y | -7.28 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 185.80 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-11.70 | ||||
4.84 | ||||
38.50 | ||||
10.60 | ||||
-21.20 | ||||
-1.93 | ||||
4.84 | ||||
5.97 | ||||
2.88B | ||||
Forward PE | -6.52 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.10 | ||||
3.20 | ||||
0.06 | ||||
0.08 | ||||
- | ||||
Leverage Ratio | 1.50 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-282.30 | ||||
-274.80 | ||||
- | ||||
8.38 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
98.18M | ||||
0.72 | ||||
-1.45 | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -0.86 | 1.30 | 251.16 |
Q01 2023 | -0.71 | -0.80 | -12.68 |
Q04 2022 | -0.78 | -0.75 | 3.85 |
Q03 2022 | -0.83 | -0.84 | -1.20 |
Q02 2022 | -0.52 | -0.48 | 7.69 |
Q01 2022 | -0.47 | -0.53 | -12.77 |
Q04 2021 | -0.41 | -0.62 | -51.22 |
Q03 2021 | -0.51 | -0.69 | -35.29 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | -0.83 | 7.78 | Positive |
12/2023 QR | -0.89 | 4.30 | Positive |
12/2023 FY | -1.23 | 65.16 | Positive |
12/2024 FY | -3.16 | 8.41 | Positive |
Next Report Date | 2nd Nov 2023 |
Estimated EPS Next Report | -0.83 |
Estimates Count | 12 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1.03M |
Shares Outstanding | 137.42K |
Shares Float | 106.23M |
Trades Count | 13.89K |
Dollar Volume | 20.86M |
Avg. Volume | 737.47K |
Avg. Weekly Volume | 824.48K |
Avg. Monthly Volume | 793.96K |
Avg. Quarterly Volume | 593.98K |
Denali Therapeutics Inc. (NASDAQ: DNLI) stock closed at 19.79 per share at the end of the most recent trading day (a -4.07% change compared to the prior day closing price) with a volume of 1.56M shares and market capitalization of 2.85B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 291 people. Denali Therapeutics Inc. CEO is Ryan J. Watts.
The one-year performance of Denali Therapeutics Inc. stock is -36.24%, while year-to-date (YTD) performance is -28.84%. DNLI stock has a five-year performance of -6.65%. Its 52-week range is between 19.67 and 34.78, which gives DNLI stock a 52-week price range ratio of 7.15%
Denali Therapeutics Inc. currently has a PE ratio of -11.70, a price-to-book (PB) ratio of 4.84, a price-to-sale (PS) ratio of 38.50, a price to cashflow ratio of 10.60, a PEG ratio of -, a ROA of -24.64%, a ROC of -31.02% and a ROE of -36.26%. The company’s profit margin is 8.38%, its EBITDA margin is -274.80%, and its revenue ttm is $98.18 Million , which makes it $0.72 revenue per share.
Of the last four earnings reports from Denali Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.83 for the next earnings report. Denali Therapeutics Inc.’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for Denali Therapeutics Inc. is Strong Buy (1.29), with a target price of $60.92, which is +193.59% compared to the current price. The earnings rating for Denali Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Denali Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Denali Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.59, ATR14 : 0.86, CCI20 : -156.99, Chaikin Money Flow : -0.23, MACD : -1.01, Money Flow Index : 28.08, ROC : -18.12, RSI : 23.42, STOCH (14,3) : 2.44, STOCH RSI : 0.00, UO : 26.67, Williams %R : -97.56), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Denali Therapeutics Inc. in the last 12-months were: Alexander O. Schuth (Option Excercise at a value of $136 200), Alexander O. Schuth (Sold 30 566 shares of value $856 489 ), Carole Ho (Sold 40 269 shares of value $1 115 668 ), Krognes Steve (Sold 6 466 shares of value $190 770 ), Marc Tessier-Lavigne (Sold 40 000 shares of value $1 215 063 ), Ryan J. Watts (Option Excercise at a value of $51 000), Ryan J. Watts (Sold 97 077 shares of value $2 759 474 ), SATO VICKI L (Sold 1 666 shares of value $49 709 ), Schuth Alexander (Sold 0 shares of value $-189 000 ), Schuth Alexander (Sold 51 191 shares of value $1 391 545 ), Steve E. Krognes (Sold 6 466 shares of value $190 770 ), Vicki L. Sato (Sold 3 332 shares of value $90 193 ), Watts Ryan (Sold 0 shares of value $-52 718 ), Watts Ryan (Sold 101 912 shares of value $2 874 860 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
CEO: Ryan J. Watts
Telephone: +1 650 866-8548
Address: 161 Oyster Point Boulevard, South San Francisco 94080, CA, US
Number of employees: 291
Wed, 09 Aug 2023 11:58 GMT Denali Therapeutics price target lowered to $31 from $37 at Wedbush
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.